MDS Trials

Imetelstat for patients with highly transfusion-dependent MDS

The initial treatment option for patients with lower-risk MDS is the use of erythropoiesis-stimulating agents (ESAs) with/without other...

Does imetelstat provide transfusion independence in lower-risk MDS?

During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uwe Platzbecker, Leipzig University...

Decitabine plus cedazuridine approved by the FDA for MDS

On July 7, 2020, the U.S. Food and Drug Administration (FDA) approved the oral combination of decitabine with cedazuridine (ASTX727) to treat...

Oral cedazuridine/decitabine offers comparable efficacy and safety to IV decitabine in MDS and CMML, with enhanced QoL opportunities

The oral bioavailability of decitabine is limited due to rapid...